Jagsonpal Pharmaceuticals Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.5K Cr
Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25 on a stable basis. Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25.
From Jagsonpal Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹237
Market Cap
₹1.5K Cr
P/E Ratio
31.8
How does Jagsonpal Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Jagsonpal Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹64 Cr, net profit ₹9 Cr.
Full financials →📊 Revenue & Sales Performance
- →Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25 on a stable basis.
- →Growth drivers include approximately one-third volume growth, one-third price increases (3-5%), and one-third new product launches.
- →Recent product launches like FeProtein and LycoRed M are gaining traction, crossing INR 20 lakhs monthly sales.
- →The company expects continued organic growth in the base business, with an 8% organic growth rate YTD.
- →New product introductions are planned at 8-10 products annually, about two per division across four divisions.
- →No major changes in product mix expected organically; portfolio shifts will occur mainly through inorganic acquisitions.
- →Trade generics and highly doctor-intensive portfolios help maintain stable demand.
- →MR productivity improvement and maintaining current MR strength support volume growth.
📈 Profitability & Margins
- →Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25.
- →Organic growth is inching up to 8%, supported by price increases, volume growth, and new product launches (each contributing about one-third).
- →EBITDA margin is expected to expand by 120 to 150 basis points year-on-year.
- →Operating EBITDA margin guidance is between 22% and 23%, consistent with current performance.
- →The company anticipates margin improvement chiefly from MR productivity and scale, with manufacturing playing a minor role.
- →Net profit growth has been strong, e.g., 190% growth in Q3 YoY, but future guidance focuses on steady growth aligned with revenues and margin expansions.
- →New product launches (8 to 10 per year) will support future earnings growth.
- →Inorganic growth via acquisitions is likely to impact portfolio mix and contribute to future profitability gains.
🏗️ Capital Expenditure Plans
- →No specific mention of current or future capital expenditure (capex) or strategic investments in manufacturing or infrastructure was highlighted.
- →The company emphasized a disciplined approach to cash utilization, prioritizing:
- → - Inorganic growth opportunities such as acquisitions that fit strategic and pricing criteria.
- → - No expansion in MR (Medical Representative) strength planned; focus is on productivity.
- →Cash balance expected to reach around INR 150 crores by year-end, generated mostly from operations and divestment of the Faridabad facility.
- →No complex accounting or manufacturing investments are currently planned, indicating a focus on organic growth and operational efficiency.
- →Strategic investments are expected to be India-centric and focused on filling portfolio gaps or expanding therapeutic presence through acquisitions.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
- →Cash balances are strong and growing, with a target to reach around INR 150 crores by year-end, supported by operational cash flows and asset sales.
- →The company plans to use cash primarily for disciplined inorganic growth opportunities (acquisitions) that fit strategic and valuation criteria.
- →Management indicated a disciplined approach towards acquisitions but did not specify any need for external fundraising.
- →No mention of issuing new equity or taking on debt was made; focus is on utilizing existing cash reserves.
- →If shareholders demand, surplus cash could be returned via dividends, indicating preference against raising external capital currently.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q3 FY25 results?
Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25 on a stable basis. Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25.
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
No specific mention of current or future capital expenditure (capex) or strategic investments in manufacturing or infrastructure was highlighted.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.